Inactive Instrument

Cubist Pharmaceuticals Inc Stock

Stocks

End-of-day quote Nasdaq
- ^USD	-

10/12/14	Cubist Pharmaceuticals : sales force seen as potential boon for Merck intestinal drug	RE
09/12/14	Cubist Pharmaceuticals : Merck says still plans to buy Cubist, despite patent setback	RE

10/12/14	Cubist Pharmaceuticals : sales force seen as potential boon for Merck intestinal drug	RE
09/12/14	Cubist Pharmaceuticals : Merck says still plans to buy Cubist, despite patent setback	RE
09/12/14	Merck : to take on superbugs with Cubist Pharma buy	RE
09/12/14	AstraZeneca : Merck to take on superbugs with Cubist Pharma buy	RE
09/12/14	Apple : S&P 500 posts worst day since Oct; energy shares sink	RE
08/12/14	Cubist Pharmaceuticals : options unusually active before Merck deal	RE
06/12/14	Cubist Pharmaceuticals : Merck in talks to acquire Cubist Pharmaceuticals for more than $7 billion - NYT	RE
21/05/13	Cubist Pharmaceuticals Inc : U.S. court ruling favors Cubist in patent case versus Hospira	RE

13/01/15	Cubist Pharmaceuticals : Announces Withdrawal of Listing of CVRs (CBSTZ) from NASDAQ Global Select Market	BU
20/12/14	Cubist Pharmaceuticals : Announces FDA Approval of New Antibiotic ZERBAXA™ (Ceftolozane/Tazobactam) for Complicated Urinary Tract and Complicated Intra-abdominal Infections	BU
09/12/14	Cubist Pharmaceuticals : Ryan & Maniskas, LLP : Announces Investigation of Cubist Pharmaceuticals Inc.	PR
09/12/14	Cubist Pharmaceuticals : Comments on CUBICIN Patent Litigation	BU
08/12/14	CUBIST PHARMACEUTICALS : ALERT: Johnson & Weaver, LLP Investigates the Fairness of Price and Process in Proposed Sale of Cubist Pharmaceuticals, Inc. to Merck	BU

21/12/14	Cubist Pharmaceuticals : meldet FDA-Zulassung seines neuen Antibiotikums ZERBAXA™ (Ceftolozan/Tazobactam) für komplizierte Harnwegsinfektionen und komplizierte intraabdominelle Infektionen
20/12/14	Cubist Pharmaceuticals : annonce l’approbation par la FDA du nouvel antibiotique ZERBAXA™ (ceftolozane/tazobactam) pour le traitement des infections urinaires compliquées et des infections intra-abdominales compliquées
09/12/14	Merck : compte toujours acheter Cubist malgré un souci sur le Cubicin
08/12/14	Cubist Pharmaceuticals : Merck & Co acquiert Cubist Pharma pour 8,4 milliards de dollars
08/12/14	Cubist Pharmaceuticals : Wall Street ouvre en baisse, l'Asie inquiète

Manager	Title	Age	Since
Karen Rogers PRN	Corporate Officer/Principal	-	-
Phyllis Rae Abbuhl SAM	Sales & Marketing	-	-
Frederick B. Oleson PRN	Corporate Officer/Principal	-	01/01/1997

Director	Title	Age	Since
Martin Hermanus Soeters BRD	Director/Board Member	72	01/09/2006
Kenneth J. Martin BRD	Director/Board Member	72	25/09/2013

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
MODERNA, INC.	-1.36%	+11.24%	+659.46%	+91.85%	79.4B
REGENERON PHARMACEUTICALS, INC.	-3.48%	-4.87%	+35.41%	-9.02%	78.69B
CSL LIMITED	+2.80%	+2.02%	-8.59%	-27.82%	59.52B
UCB	-0.51%	+0.57%	-6.28%	+173.81%	46.58B
SAMSUNG BIOLOGICS CO.,LTD.	-1.80%	-2.29%	-11.16%	+30.46%	46.53B
BIOGEN INC.	+0.13%	+4.26%	+64.89%	-11.41%	33.63B
INCYTE CORPORATION	-0.31%	-0.81%	+47.38%	+110.95%	25.11B
INNOVENT BIOLOGICS, INC.	-3.56%	-6.10%	+2.72%	+140.98%	22.13B
SWEDISH ORPHAN BIOVITRUM AB	+0.28%	-1.13%	+56.98%	+96.68%	15.31B
Average	-0.86%	+4.05%	+93.42%	+66.28%	45.21B
Weighted average by Cap.	-0.98%	+6.45%	+142.86%	+52.70%

Employees

Sector